找考题网-背景图
单项选择题

[A] Whether research should be done on embryonic stem c……

Jonas Frisen had his eureka moment in 1997. Back then, scientists suspected that there was a special type of cell in the brain that had the power to give rise to new brain cells. If they could harness these so-called neural stem cells to regenerate damaged brain tissue, they might someday find a cure for such brain diseases as Alzheimer’s and Parkinson’s. But first they had to figure out where neural stem cells were and what they looked like. Frisen, then a freshly minted Ph. D. at the Karolinska Institute in Stockholm, was peering through his microscope at some tissue taken from a rat’s injured spinal cord when he saw cells that appeared to have been enervated by the injury, as though they were busy making repairs. Frisen thought these might be the neural stem cells scientists had been looking for. It took him six years of painstaking research to make sure.
Frisen is quick to emphasize that his research is basic and that treatments are years off. But the findings so far hint at extraordinary potential. Two years ago he identified neural stem cells in the adult human brain, And he’s now researching the mechanisms by which these cells grow into different types of brain cells. Rather than growing brain tissue in a petri-dish and implanting it in, say, the forebrain of a Parkinson’s patient, doctors might someday stimulate the spontaneous growth of new neural cells merely by administering a drug. "It sounds like science fiction," Frisen says, "but we can already do it in mice." In 2007 he will publish the results of his recent experiments. He’s isolated a protein in the mouse brain that inhibits the generation of nerve cells. Using other chemicals, he’s been able to block the action of this inhibitor, which in turn leads to the production of new brain cells.
Frisen honed his analytical mind at the dinner table in Goteborg, in southwest Sweden. His mother was a mathematics professor and his father was an ophthalmologist. Frisen went to medical school intending to be a brain surgeon or perhaps a psychiatrist, but ended up spending all his free time in the lab. In 1998 he got seed money from a Swedish venture capitalist to set up his own company, NeuroNova, to commercialize his work. A private foundation tried to lure him to Texas, but Swedish businessman Marcus Storch persuaded him to stay by funding a 15-year professorship at Karolinska, covering his salary and the running costs of his 15-person lab. "Jonas Frisen stood out from all candidates by far," says Storch, whose Tobias Foundation sponsors stem-cell research. "He is something of a king in Sweden." Two years ago two more venture capitalists helped the company expand by hiring a CEO and setting up a separate lab.
Since most researchers are interested in stem cells taken from embryos, the practice has attracted considerable controversy in the past few years. Frisen has benefited indirectly from research restrictions in the United States, which have driven funds and brain-power to Singapore, the United Kingdom and Sweden. The Bush Administration currently forbids U. S. -funded work on all but 78 approved stem-cell cultures, many of which are located outside the country. In just one sign of the times, the U. S.-based Juvenile Diabetes Research Foundation recently announced grants totaling $20 million for stem-cell research—the largest award yet given to the field by a medical charity—to research institutes in Sweden and elsewhere, but not in the United States.
Since Frisen doesn’t work with embryonic stem cells, he’s unwittingly become a champion of the radical right, which argues that scientists ought to concentrate solely on adult stem cells. He happens to disagree. "It would be overoptimistic or outright stupid," he says. "To really understand adult cells, we need to master how embryonic stem cells work." But what really gets Frisen going is when people ask him when they can expect a drug for Parkinson’s and other diseases. "I say, five decades, just to get the number thing out of the way," he quips. "I’m not going to oversell this." When pressed, he admits that clinical trials might begin in five years. That would be a eureka moment worth waiting for.
On which of the following aspects does Frisen disagree with some radicals


[A] Whether research should be done on embryonic stem cells.
B. Whether research should be done on adult stem cells.
C. When should people expect a drug for Parkinson’s.
D. When should clinical trials of stem-cells research begin.
热门试题

单项选择题The last paragraph implies that [A] Today and Tomorrow provides technological solutions for manufacturers. [B] Many of the Japanese innovations are inspired by Today and Tomorrow. [C] Today and Tomorrow is more popular among the Japanese than the Americans. [D] Today and Tomorrow is a Japanese manufacturing encyclopedia.

A revolutionary manufacturing process made it possible for anyone to own a car. Henry Ford is the man who put the world on wheels.
When it comes to singling out those who have made a difference in all our lives, you cannot overlook Henry Ford. A historian a century from now might well conclude that it was Henry Ford who most influenced all manufacturing everywhere, even to this day, by introducing a new way to make cars—one, strange to say, that originated in slaughter houses.
Back in the early 1900s, slaughter houses used what could have been called a "disassembly line." That is, the carcass of a slain steer or a pig was moved past various meat-cutters, each of whom cut off only a certain portion. Ford reversed this process to see if it would speed up production of a part of an automobile engine called a magneto. Rather than have each worker completely assemble a magneto, one of its elements was placed on a conveyer, and each worker, as it passed, added another component to it, the same one each time. Professor David Hounshell, of The University of Delaware, an expert on industrial development tells what happened: "The previous day, workers carrying out the entire process had averaged one magneto every 20 minutes. But on that day, on the line, the assembly team averaged one every 13 minutes and 10 seconds per person."
Within a year, the time had been reduced to five minutes. In 1913, Ford went all the way. Hooked together by ropes, partially assembled vehicles were towed past workers who completed them one piece at a time. It wasn’t long before Ford was turning out several hundred thousand cars a year, a remarkable achievement then. And so efficient and economical was this new system that he cut the price of his cars in half, to $260, putting them within reach of all those who, up until that time, could not afford them. Soon, auto makers over the world copied him. In fact, he encouraged them to do so by writing a book about all of his innovations, entitled Today and Tomorrow. The Age of the Automobile had arrived. Today, aided by robots and other forms of automation, everything from toasters to perfumes is made on assembly lines.
Edsel Ford, Henry’s great-grandson, and a Ford vice president: “I think that my great-grandfather would just be amazed at how far technology has come."
Many of today’s innovations come from Japan. Norman Bodek, who publishes books about manufacturing processes, finds this ironic. On a recent trip to Japan he talked to two of the top officials of Toyota. "When I asked them where these secrets came from, where their ideas came from to manufacture in a totally different way, they laughed, and they said. ’Well. We just read it in Henry Ford’s book from 1926: Today and Tomorrow.’\